Zealand Pharma today hosts a Capital Market Day and Site Visit
4/6/2011 3:57 AM EST
Zealand Pharma A/S
Investor News
Zealand Pharma today hosts a Capital Market Day and Site Visit
A live webcast of the event will be accessible from the company's website
Copenhagen, 2011-04-06 09:57 CEST (GLOBE NEWSWIRE) -- Investor News
No. 06/2011
Zealand Pharma today hosts a Capital Market Day and Site Visit
Wednesday, 6 April 2011 from 12:00 to 4:30pm CEST
A live webcast of the event will be accessible from the company's website
Copenhagen, 6 April 2011 - Zealand Pharma (NASDAQ OMX: ZEAL), a Scandinavian
based biopharmaceutical company hosts a capital market day and site visit at
its Copenhagen headquarters today from 12:00 to 16:30 CEST.
The Zealand Pharma management team will present a business overview focussing
on the company's strategy and the status of the company's pipeline of novel
peptide drugs, including lixisenatide, a novel GLP-1 drug in late-stage Phase
III development for the treatment of Type 2 Diabetes in collaboration with
sanofi-aventis. No new material information will be disclosed.
The event also features a keynote speech by Dr. Bernard Charbonnel, Chair of
the Department of Medicine at the Université de Nantes, on the outlook for
diabetes treatment and the impact of GLP-1 and new insulin treatments.
A live webcast and replay of the event can be accessed via the IR section of
the company's website at http://ir.zealandpharma.com/.
The live webcast will begin at 12:00 CEST and finish at 16:30 CEST, with a
break from 12:50 to 14:00 CEST for the site visit.
# # #
For further information, please contact:
Zealand Pharma
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications
Tel: +45 8877 3689 or Mobile: +45 5060 3689,
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) Scandinavian based
biopharmaceutical company with a mature and growing clinical pipeline of
innovative peptide drugs. The company's lead product candidate is a once-daily
GLP-1 in late-stage Phase III development for the treatment of Type 2 Diabetes
in collaboration with sanofi-aventis. Zealand Pharma also has several other
collaboration and licensing partnerships, including a license agreement with
Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of
Chemotherapy and Radiotherapy Induced Diarrhoea.
Zealand Pharma has unique expertise in peptide discovery and optimization and
in the development of novel peptide drugs with favourable therapeutic
attributes. The company targets metabolic (diabetes and obesity),
gastrointestinal and cardiovascular diseases, where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high. All of Zealand Pharma's
product candidates have been identified through the company's own drug
discovery activities. The company is headquartered in Copenhagen and has
approximately 90 employees. For more information please visit
www.zealandpharma.com